D. Boral Capital Reaffirms “Buy” Rating for Citius Pharmaceuticals (NASDAQ:CTXR)

D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a research report released on Monday,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.

A number of other brokerages have also commented on CTXR. Citigroup lowered shares of Citius Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 23rd. Maxim Group downgraded Citius Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Citius Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $54.50.

Citius Pharmaceuticals Trading Down 4.7%

NASDAQ:CTXR opened at $1.01 on Monday. The company’s 50 day moving average price is $0.85 and its 200-day moving average price is $2.02. Citius Pharmaceuticals has a 52 week low of $0.65 and a 52 week high of $26.25.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.19). Sell-side analysts expect that Citius Pharmaceuticals will post -4.5 EPS for the current year.

Institutional Trading of Citius Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its stake in shares of Citius Pharmaceuticals by 103.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock worth $33,000 after acquiring an additional 4,168 shares during the last quarter. Fisher Asset Management LLC bought a new stake in Citius Pharmaceuticals during the fourth quarter valued at about $51,000. Finally, IFP Advisors Inc raised its stake in shares of Citius Pharmaceuticals by 21.2% in the fourth quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock worth $162,000 after buying an additional 7,083 shares during the period. 16.88% of the stock is currently owned by institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.